Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TROP2-targeted anti-Frizzled bispecific antibody
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TROP2-targeted anti-Frizzled bispecific antibody is an experimental bispecific antibody developed by Genentech to selectively inhibit the Wnt signaling pathway in tumor cells. The antibody is designed to address the dose-limiting intestinal toxicities typically associated with systemic Wnt inhibition, which occur because Wnt signaling is essential for normal intestinal homeostasis. By utilizing TROP2 (Trophoblast cell-surface antigen 2) as a tumor-selective anchor—a receptor highly expressed in various epithelial cancers but absent in Wnt-dependent normal intestinal stem cells—the antibody selectively delivers a potent Wnt-inhibitory signal to tumor tissues. It simultaneously binds to TROP2 and Frizzled (FZD) receptors, effectively blocking oncogenic Wnt signaling and suppressing tumor growth in preclinical models of colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) with minimal impact on normal intestinal tissue.
- Other names
- TROP2-targeted Wnt inhibitorTROP-2-targeted Wnt inhibitorTROP 2-targeted Wnt inhibitorTROP2-FZD bispecific antibodyTROP-2-FZD bispecific antibodyTROP 2-FZD bispecific antibody
02
Targets
FZD (Frizzled receptor family)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on TROP2-targeted anti-Frizzled bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TROP2-targeted anti-Frizzled bispecific antibody.